Mobia Medical (NASDAQ:MOBI) Announces Quarterly Earnings Results

Mobia Medical (NASDAQ:MOBI) announced its earnings results on Thursday. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.06), FiscalAI reports. The company had revenue of $15.62 million during the quarter. The business’s revenue was up 73.3% on a year-over-year basis.

Here are the key takeaways from Mobia Medical’s conference call:

• Third-quarter revenue rose 73% year over year to $15.6 million, ahead of expectations, prompting Mobia to raise its 2026 revenue outlook to $57.0 million–$57.5 million from $54 million–$56 million.
• Growth was driven disproportionately by adoption at existing programs, while average active territories increased 78% year over year to 40. Management said it plans to keep adding territories at a measured, consistent pace.
• Mobia pointed to the inclusion of paired vagus nerve stimulation in updated AHA/ASA stroke recovery guidelines and favorable reimbursement infrastructure, including a Category 1 CPT code and an average Medicare payment of about $45,000, as factors supporting adoption. Management said the recent OPPS rule supports its reimbursement strategy.
• Operating expenses increased to $31.5 million from $18.4 million, largely reflecting commercial hiring and higher stock-based compensation, and the quarterly net loss widened to $17.3 million from $11.4 million. The company reported $160.7 million in cash and said it expects gross margin to remain in the low 80% range.

Mobia Medical Price Performance

MOBI traded down $0.09 during trading on Friday, reaching $11.19. 223,810 shares of the company’s stock were exchanged, compared to its average volume of 147,839. The stock has a fifty day moving average of $10.00. The stock has a market capitalization of $372.52 million and a PE ratio of -0.55. Mobia Medical has a 1 year low of $8.03 and a 1 year high of $15.29. The company has a debt-to-equity ratio of 0.04, a current ratio of 13.28 and a quick ratio of 12.80.

Insider Activity

In related news, Director Casey Tansey bought 35,572 shares of the stock in a transaction dated Thursday, August 13th. The shares were purchased at an average price of $11.51 per share, for a total transaction of $409,433.72. Following the completion of the purchase, the director directly owned 268,904 shares of the company’s stock, valued at $3,095,085.04. This represents a 15.25% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders bought 87,000 shares of company stock valued at $1,016,367.

Hedge Funds Weigh In On Mobia Medical

Several institutional investors have recently made changes to their positions in MOBI. University of Texas Texas AM Investment Management Co. acquired a new stake in Mobia Medical during the third quarter valued at $1,019,000. State Street Corp acquired a new position in shares of Mobia Medical in the second quarter worth about $735,000. Citadel Advisors LLC acquired a new position in shares of Mobia Medical in the second quarter worth about $670,000. Finally, Readystate Asset Management LP purchased a new stake in shares of Mobia Medical during the 2nd quarter worth about $134,000.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on MOBI shares. BTIG Research restated a “buy” rating and set a $20.00 price target on shares of Mobia Medical in a research note on Friday. Weiss Ratings started coverage on shares of Mobia Medical in a report on Wednesday, August 12th. They issued a “sell (e-)” rating for the company. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Mobia Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Mobia Medical presently has a consensus rating of “Moderate Buy” and an average price target of $21.00.

About Mobia Medical

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.